Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

D'Addario, 2010, Guidelines Working Group. . Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, v116, 10.1093/annonc/mdq189 Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954 Pirker, 2009, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9 Carmeliet, 2011, Molecular mechanisms and clinical applications of angiogenesis, Nature, 473, 298, 10.1038/nature10144 Yano, 2003, Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules, Cancer Sci, 94, 479, 10.1111/j.1349-7006.2003.tb01469.x Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Reck, 2009, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL, J Clin Oncol, 27, 1227, 10.1200/JCO.2007.14.5466 Reck, 2010, Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), Ann Oncol, 21, 1804, 10.1093/annonc/mdq020 Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022 Heymach, 2008, Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer, J Clin Oncol, 26, 5407, 10.1200/JCO.2008.17.3138 Goss, 2010, Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study, J Clin Oncol, 28, 49, 10.1200/JCO.2009.22.9427 Scagliotti, 2010, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer, J Clin Oncol, 28, 1835, 10.1200/JCO.2009.26.1321 Paz-Ares, 2012, Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer, J Clin Oncol, 30, 3084, 10.1200/JCO.2011.39.7646 Polverino, 2006, AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts, Cancer Res, 66, 8715, 10.1158/0008-5472.CAN-05-4665 Coxon, 2012, Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models, Mol Cancer, 11, 70, 10.1186/1476-4598-11-70 Sherman, 2008, Motesanib diphosphate in progressive differentiated thyroid cancer, N Engl J Med, 359, 31, 10.1056/NEJMoa075853 Schlumberger, 2009, Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer, J Clin Oncol, 27, 3794, 10.1200/JCO.2008.18.7815 Martin, 2011, Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study, Lancet Oncol, 12, 369, 10.1016/S1470-2045(11)70037-7 Rosen, 2007, Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors, J Clin Oncol, 25, 2369, 10.1200/JCO.2006.07.8170 Scagliotti, 2012, International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1, J Clin Oncol, 30, 2829, 10.1200/JCO.2011.41.4987 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Cancer Therapy Evaluation Program Cox, 1984 Kotasek, 2011, Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study, BMC Cancer, 11, 313, 10.1186/1471-2407-11-313 Tebbutt, 2011, The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors [abstract], J Clin Oncol, 29, e13555, 10.1200/jco.2011.29.15_suppl.e13555 Blumenschein, 2011, A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer, Ann Oncol, 22, 2057, 10.1093/annonc/mdq731 Blumenschein, 2010, Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer, Clin Cancer Res, 16, 279, 10.1158/1078-0432.CCR-09-1675 Burris, 2011, Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-cisplatin in patients with advanced cancer, J Oncol, 2011, 853931, 10.1155/2011/853931 Price, 2008, Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours, Br J Cancer, 99, 1387, 10.1038/sj.bjc.6604723 Lynch, 2010, Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099, J Clin Oncol, 28, 911, 10.1200/JCO.2009.21.9618 Lara, 2011, Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer, J Clin Oncol, 29, 2965, 10.1200/JCO.2011.35.0660 Pajares, 2012, Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung, J Clin Oncol, 30, 1129, 10.1200/JCO.2011.37.4231 Hainsworth, 2011, BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer, J Thorac Oncol, 6, 109, 10.1097/JTO.0b013e3181f94ad4